SAREPTA THERAPEUTICS Q2 EARNINGS CONFERENCE CALL, AUGUST 8, 2018 FORWARD-LOOKING STATEMENTS

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements by management relating to our future operations, financial performance and projections, business plans, priorities and research and development programs including: Sarepta's strategic vision of becoming one of the most meaningful global genetic medicine companies while continuing to remain focused on executing on its plans and fulfilling its commitments; Sarepta remaining on track to achieve its 2018 quidance of \$295 - \$305 million; the expectation that the CHMP will hold a SAG meeting in the fall of 2018 and that a final decision will be made by year-end; our belief that we have a strong case for access to eteplirsen for patients with exon 51 amenable mutations in Europe: the estimated market opportunity for our product candidates, including golodirsen, casimersen and our LGMD product candidates; our expectation that the clinical hold on our micro-dystrophin trial will be lifted in advance of our meeting with the FDA to align on our clinical pathway; Sarepta's plan to make a \$30 million equity investment is Lacerta and to lead clinical development and commercialization of Lacerta's programs; payments that Sarepta is expected to make under the agreements with Lacerta; the potential benefits of our partnership with Lacerta, including access to world-class talent and potential gene therapy tools and expansion of our gene therapy pipeline; our expectation to nearly double the number of employees we had at the beginning of 2018 by the end of 2018; the expectation that the partnership with Brammer Bio will provide us with sufficient commercial supply for our micro-dystrophin gene therapy launch, under the most aggressive development assumptions; building our gene therapy center of excellence; our strong foundation uniquely positioning us to execute on our strategic vision; our intention to continue to thoughtfully manage our expenses and to economically move multiple programs forward in parallel; our plan to keep our approach to managing our finances and building shareholder value the same; our expectation that the average age of patients will not change dramatically until newborn screening for Duchenne becomes standard medical practice, which would identify hundreds of new patients with DMD; our global expansion plans; the U.S. commercial success of EXONDYS 51 providing the framework and resources to support future rare disease launches; key areas and catalysts for the remaining of 2018; and expected milestones and timelines, including the submission of an NDA for golodirsen by year-end, with a target approval in 2019, performing an analysis for dystrophin expression before the end of 2018 for the purpose of supporting a potential accelerated approval for casimersen by mid-2019, getting PPMO dosing insights in the first quarter of 2019, holding a Type B FDA meeting to align on the clinical pathway for our micro-dystrophin registration trial and commencing the next trial before the end of 2018, responding to the FDA's clinical hold letter before the end of August, and dosing the first patient in the LGMD 2E program in August.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to EXONDYS 51 sales or attain the net revenues we anticipate for 2018, profitability or positive cash-flow from operations; the CHMP may render a negative final decision and we may not be able to obtain regulatory approval for eteplirsen from the EMA; Sarepto's dependence on Brammer Bio to produce its product andidates, including any inability on Sarepto's part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; the expected benefits and opportunities related to the transactions with Lacerta may not be realized or may take longer to realize than expected due to challenges and uncertainties inherent in product research and development; the partnership with Lacerta may not result in any viable treatments suitable for clinical research or commercialization due to a variety of reasons including the results of future research may fail to meet regulatory approval requirements for the safety and efficacy of product candidates and any potential future inability of the parties to fulfill their commitments and obligations under the agreements; there is no assurance that the FDA's requirements will be met and that the clinical hold on the micro-dystrophin trial will be lifted in the expected timeframe, or at all. If the Clinical Hold is not lifted in the expected timeframe, the development of our micro-dystrophin gene therapy product candidate may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize this product candidate; there is no assurance that we will be able to rely o

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.